Publications
March 31, 2025
Effect of Targeting apoC-III with Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia
Read MoreDecember 10, 2024
Preclinical and Clinical Pharmacokinetics of JNJ-75220795, an siRNA Therapeutic Targeting PNPLA3, for Metabolic Dysfunction-Associated Steatohepatitis
Read MoreSeptember 2, 2024
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
Read MoreJuly 11, 2024
Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)
Read MoreMay 28, 2024
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
Read MoreApril 30, 2024
A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2a in Patients with Advanced Clear Cell Renal Cell Carcinoma
Read MoreApril 7, 2024
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia - The SHASTA-2 Randomized Clinical Trial
Read MoreAugust 25, 2023
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts
Read MoreMarch 20, 2023
Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment
Read MoreDecember 15, 2022
HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Read MoreDecember 10, 2022
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
Read MoreDecember 9, 2022
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
Read MoreNovember 22, 2022
Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants, Clinical Pharmacology in Drug Development
Read MoreNovember 17, 2022
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
Read MoreOctober 30, 2022
Plasma and Liver Pharmacokinetics of the N-Acetylgalactosamine Short Interfering RNA JNJ-73763989 in Recombinant Adeno-Associated-Hepatitis B Virus-Infected Mice
Read MoreSeptember 30, 2022
Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study
Read MoreSeptember 30, 2022
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)
Read MoreAugust 11, 2022
Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency
Read MoreJuly 20, 2022
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB
Read MoreJune 7, 2022
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B
Read MoreApril 30, 2022
Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment
Read MoreJanuary 13, 2022
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
Read MoreMarch 30, 2021
RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies
Read MoreApril 23, 2020
RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection
Read MoreJanuary 9, 2020
Role of angiopoietin-like protein 3 in sugar-induced dyslipidemia in rhesus macaques: suppression by fish oil or RNAi
Read MoreFebruary 5, 2019
Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference
Read MoreMarch 21, 2018
Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients
Read MoreSeptember 27, 2017
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg
Read MoreAugust 30, 2015
Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes
Read MoreJune 27, 2015
Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent
Read MoreJune 16, 2015
Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities
Read MoreFebruary 26, 2013
Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection
Read MoreDecember 30, 2012
Co-Injection of a Targeted, Reversibly Masked Endosomolytic Polymer Dramatically Improves the Efficacy of Cholesterol-Conjugated Small Interfering RNAs In Vivo
Read MoreSeptember 18, 2012
Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies
Read MoreMay 1, 2011
Current status of pharmaceutical and genetic therapeutic approaches to treat DMD
Read MoreApril 18, 2011
Dose response in rodents and nonhuman primates after hydrodynamic limb vein delivery of naked plasmid DNA
Read MoreFebruary 2, 2011
Muscle damage after delivery of naked plasmid DNA into skeletal muscles is batch dependent
Read MoreJuly 21, 2010
Hybrid PET/CT for noninvasive pharmacokinetic evaluation of dynamic PolyConjugates, a synthetic siRNA delivery system
Read MoreApril 30, 2010
Use of Evans blue dye to compare limb muscles in exercised young and old mdx mice
Read MoreFebruary 1, 2010
Functional efficacy of dystrophin expression from plasmids delivered to mdx mice by hydrodynamic limb vein injection
Read MoreAugust 7, 2007
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
Read MoreMarch 2, 2007
PPARα siRNA–Treated Expression Profiles Uncover the Causal Sufficiency Network for Compound-Induced Liver Hypertrophy | PLOS Computational Biology
Read MoreMarch 1, 2007
Progress toward a nonviral gene therapy protocol for the treatment of anemia
Read MoreMarch 1, 2007
Magnetic resonance imaging-monitored plasmid DNA delivery in primate limb muscle
Read MoreAugust 30, 2006
Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice
Read MoreJuly 30, 2006
Mechanism of plasmid delivery by hydrodynamic tail vein injection. I. Hepatocyte uptake of various molecules
Read MoreJuly 30, 2006
Hepatocyte targeting of nucleic acid complexes and liposomes by a T7 phage p17 peptide
Read MoreAugust 30, 2005
Delivery of siRNA and siRNA Expression Constructs to Adult Mammals by Hydrodynamic Intravascular Injection
Read MoreAugust 19, 2005
Long-term RNA interference from optimized siRNA expression constructs in adult mice
Read MoreAugust 30, 2004
A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs
Read More 62 Results